Convoke raises $8.6M seed from Kleiner Perkins to automate drug development planning with AI

Convoke, a drug development planning startup, has closed an $8.6 million seed round led by Mamta Malik (referred to in the transcript as Lee Maria) at Kleiner Perkins. The company is targeting the planning and preparation layer of pharmaceutical development, which founder Alex estimates consumes roughly 45% of a drug's total development lifecycle.

The core thesis is that knowledge work in pharma — synthesizing literature, structuring regulatory documents, designing trials — is currently handled almost entirely by high-cost human consultants working in Excel and PowerPoint. Software penetration in this layer is negligible. Convoke positions its AI workspace as a replacement for that consulting spend, not as a competitor to clinical execution tools or electronic lab notebooks.

“We're building a platform to automate knowledge work required to take drugs from an idea to a product that patients can use. Today we're announcing our $8.6M seed raise from Kleiner Perkins. // The planning and preparation work takes 45% of the time of a drug's life cycle. If you can speed that up and help companies make better decisions in how they synthesize information and prepare regulatory documents faster, there is a potential to really accelerate time to market. // I'm relatively bearish on patient recruitment as a space. The supply of patients far exceeds — the demand far exceeds the supply, especially as we develop more niche drugs. AI can call hundreds of people but it doesn't solve the fundamental supply chain.”

The human-versus-AI framing Alex applies is augmentation, not displacement. With roughly 20,000 proteins in the human proteome and an exponentially large combinatorial search space for drug candidates, thorough analysis is structurally impossible for human teams working at current scale. The model shifts humans into a supervisory role, reviewing AI-generated recommendations rather than conducting the underlying research themselves.

One early customer segment is medical affairs functions inside pharma companies — teams responsible for coordinating with physicians, communicating clinical programs externally, and supporting trial enrollment. That focus reflects Convoke's positioning inside the development organization, distinct from both R&D lab operations and commercial sales.

Alex is openly skeptical of AI-driven patient recruitment as an investment category. His view is that demand for trial participants structurally outpaces supply, particularly as drug development shifts toward niche indications and personalized genetic medicines. AI tools that automate outreach do not resolve the underlying scarcity of eligible patients, making that segment difficult to build durable businesses around.